Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MacroGenics, Inc. - Common Stock (NQ:MGNX)

1.850 +0.020 (+1.09%)
Streaming Delayed Price Updated: 2:12 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MacroGenics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MacroGenics, Walgreens, Vicor, and American Airlines and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Robbins LLP Reminds MacroGenics, Inc. (MGNXX) Investors of the Class Action Lawsuit and Pending Lead Plaintiff Deadline
From Robbins LLP
Via GlobeNewswire
MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Evaluating Macrogenics: Insights From 8 Financial Analysts
 
Via Benzinga
Kirby McInerney LLP Reminds MacroGenics, Inc. (MGNX) Investors of Class Action Filing and Encourages Investors to Contact the Firm
From Kirby McInerney LLP
Via Business Wire
MACROGENICS, INC. (NASDAQ: MGNX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds MacroGenics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
TOP RANKED ROSEN LAW FIRM Encourages MacroGenics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGNX
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DXC, CrowdStrike, MacroGenics, and Five Below and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Shareholder Rights Law Firm Robbins LLP Urges MGNX Stockholders to Contact the Firm for More Information About the MacroGenics, Inc. Class Action
From Robbins LLP
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DXC, CrowdStrike, MacroGenics, and Five Below and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
MACROGENICS, INC. (NASDAQ: MGNX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds MacroGenics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
MGNX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MacroGenics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ROSEN, A LEADING NATIONAL FIRM, Encourages MacroGenics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGNX
From The Rosen Law Firm PA
Via GlobeNewswire
Kirby McInerney LLP Reminds MacroGenics, Inc. (MGNX) Investors of Class Action Filing and Encourages Investors to Contact the Firm
From Kirby McInerney LLP
Via GlobeNewswire
MacroGenics, Inc. Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Against MGNX
From Robbins LLP
Via GlobeNewswire
MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vicor, American Airlines, and MacroGenics and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages MacroGenics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGNX
From The Rosen Law Firm PA
Via GlobeNewswire
MACROGENICS, INC. (NASDAQ: MGNX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds MacroGenics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
MGNX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that MacroGenics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages MacroGenics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGNX
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vicor and MacroGenics and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
MGNX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MacroGenics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
MacroGenics, Inc. Investor Notice: Robbins LLP Reminds Stockholders of the MGNX Class Action
From Robbins LLP
Via Business Wire
NASDAQ:MGNX: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against MacroGenics, Inc.
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial
MacroGenics will discontinue vobra duo for remaining mCRPC participants after five deaths. New data to be presented at ESMO 2024 conference. 
Via Benzinga
Topics Death
MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Match Group Layoffs 2024: What to Know About the Latest MTCH Job Cuts
Match Group layoffs are a hot topic on Wednesday as the dating website operator is preparing to reduce its headcount due to demand changes. 
Via InvestorPlace
Topics Workforce
Why is Macrogenics (MGNX) Stock Down 28% Today?
Macrogenics stock is down on Wednesday after MGNX investors learned that the company is discontinuing a Phase 2 clinical trial. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.